October 1, 2019
Debiopharm’s novel IAP antagonist Debio 1143 met trial goals
Swiss-based biopharmaceutical drugmaker Debiopharm presented results for its novel IAP antagonist Debio 1143 from phase two trial, for high-risk Head and Neck cancer patients, which met its primary goal of increasing treatment efficacy compared to CRT and placebo.